Anti-influenza monoclonal antibody (AIMM Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-influenza monoclonal antibody (AIMM Therapeutics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionImmunostimulantsInfluenza virus hemagglutinin glycoproteins modulators

TargetsInfluenza virus hemagglutinin glycoproteins

Therapy Area/IndicationsInfluenza, Human

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAimm Therapeutics

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsInfluenza, Human

Inactive IndicationsN/A

ATC CodeN/A